Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 5/20 | 0.63 |
| ▸ | CA1 | P00915 | 5/20 | 0.63 |
| ▸ | CA2 | P00918 | 5/20 | 0.63 |
| ▸ | CA9 | Q16790 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TYMP | P19971 | 3/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etanidazole SCHEMBL8171462 | 1.00 | LMNA (1.00) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| Etanidazole SCHEMBL9473771 | 0.99 | LMNA (0.97) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| Etanidazole SCHEMBL27849456 | 0.95 | LMNA (0.90) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| Etanidazole SCHEMBL16246698 | 0.94 | LMNA (0.88) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| Etanidazole SCHEMBL28152496 | 0.94 | LMNA (0.88) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| Etanidazole SCHEMBL7915363 | 0.89 | LMNA (0.80) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL15024639 | 0.89 | LMNA (0.80) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL368130 | 0.88 | LMNA (0.78) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL8432165 | 0.88 | LMNA (0.78) | LMNATHRBCYP2C19CYP3A4CYP2D6 | |
| SCHEMBL14499615 | 0.88 | LMNA (0.78) | LMNATHRBCYP2C19CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14200 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12570704-B2 | Functionally modified maytansinoids and compositions and methods of use thereof | University of Georgie Research Foundation, Inc. (US) | 2026-03-10 | — | — | US | claimed |
| EP-4676551-A1 | RADIATION SPACER HYDROGELS, METHODS OF FORMING, AND METHODS OF USE | Clearstream Technologies Limited (IE) | 2026-01-14 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4524131-A1 | SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | AlonBio Ltd. (IL) | 2025-03-19 | — | — | EP | claimed |
| US-12202803-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | ALONBIO LTD. (IL) | 2025-01-21 | — | — | US | claimed |
| US-20240425752-A1 | BILIRUBIN-COATED RADIO-LUMINESCENT PARTICLES | PURDUE RESEARCH FOUNDATION (US) | 2024-12-26 | — | — | US | claimed |
| EP-4086250-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2024-12-11 | — | — | EP | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| CN-1261803-A | Antioxidant enhancement of therapy for hyperproliferative conditions | ATHEROGENICS INC (US) | 2000-08-02 | — | — | CN | claimed |
| WO-2000043045-A1 | METHOD FOR IMPROVED RADIATION THERAPY | PHOTOGEN, INC. (US) | 2000-07-27 | — | — | WO | claimed |
| WO-2000018439-A2 | USE OF NEOANGIOGENESIS MARKERS FOR DIAGNOSING AND TREATING TUMOURS BY THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-04-06 | — | — | WO | claimed |
| WO-1999030693-A2 | A DOUBLE CAPSULE FOR THE ADMINISTRATION OF ACTIVE PRINCIPLES IN MULTIPLE THERAPIES | AXCAN PHARMA INC. (CA) | 1999-06-24 | — | — | WO | claimed |
| WO-1999012548-A1 | TREATMENT OF INFLAMMATORY CONDITIONS | THERAMARK LIMITED (GB) | 1999-03-18 | — | — | WO | claimed |
| US-5612310-A | ANTITUMOR AGENTS AND NITRIC OXIDE SCAVENGERS, REDUCING BLOOD FLOW, HYPOXIC CYCLOTOXIN FOR CARDIOVASCULAR DISORDERS | DUKE UNIVERSITY (US) | 1997-03-18 | — | — | US | claimed |
| US-5554638-A | ADMINISTERING NITRIC OXIDE SYNTHASE INHIBITOR AND HYPOXIC CYTOTOXIN | DUKE UNIVERSITY (US) | 1996-09-10 | — | — | US | claimed |
| US-5192784-A | Physical and chemical stability | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-03-09 | — | — | US | claimed |
| EP-0359347-B1 | COVALENTLY-LINKED COMPLEXES AND METHODS FOR ENHANCED CYTOTOXICITY AND IMAGING | NEORX CORPORATION (US) | 1992-12-23 | — | — | EP | claimed |
| EP-0287317-A2 | Platinum complexes with one radiosensitizing ligand | THE BRITISH COLUMBIA CANCER FOUNDATION (CA) | 1988-10-19 | — | — | EP | claimed |